ReviewBioengineered
Bioengineered probiotics, a strategic approach to control enteric infections.
Review in Bioengineered. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 68 citations in OpenAlex.
- Dynamic changes of intestinal flora in patients with irritable bowel syndrome combined with anxiety and depression after oral administration of enterobacteria capsules.Bioengineered · 2021Trial
- A Non-genotoxic Variant of Escherichia coli Nissle 1917 EcN 2.0 Overexpressing Microcins Reduces Intestinal Carriage of ST131 ESBL-Producing Escherichia coli.Probiotics and antimicrobial proteins · 2026Article
- Being a better version of yourself: genetically engineered probiotic bacteria as host defense enhancers in the control of intestinal pathogens.Gut microbes · 2025Review
- The Gut Mycobiome for Precision Medicine.Journal of fungi (Basel, Switzerland) · 2025Review
- Action and immunomodulatory mechanisms, formulations, and safety concerns of probiotics.Bioscience of microbiota, food and health · 2025Review
- Assessment of Biofilm Formation and Anti-Inflammatory Response of a Probiotic Blend in a Cultured Canine Cell Model.Microorganisms · 2024Article
- Delivery of a sebum modulator by an engineered skin microbe in mice.Nature biotechnology · 2024Article
- Probing the functional and therapeutic properties of postbiotics in relation to their industrial application.Food science & nutrition · 2023Review
- Antimicrobial Effects of Different Synbiotic Compounds against Pathogenic Bacteria Isolated from Beef, Mutton, and Chicken.Archives of Razi Institute · 2022Article
- Anti-cancer activity of human gastrointestinal bacteria.Medical oncology (Northwood, London, England) · 2022Review
- Potential Application of Living Microorganisms in the Detoxification of Heavy Metals.Foods (Basel, Switzerland) · 2022Review
- Evaluation of the Role of Probiotics As a New Strategy to Eliminate Microbial Toxins: a Review.Probiotics and antimicrobial proteins · 2022Review
- Bacteriophage Cocktail and Microcin-Producing ProbioticFrontiers in microbiology · 2022Article
- Functional foods as a formulation ingredients in beverages: technological advancements and constraints.Bioengineered · 2021Review
- Role of probiotics in prevention and treatment of enteric infections: a comprehensive review.3 Biotech · 2021Review
- A Single Plasmid of Nisin-Controlled Bovine and Human Lactoferrin Expressing Elevated Antibacterial Activity of Lactoferrin-Resistant Probiotic Strains.Antibiotics (Basel, Switzerland) · 2021Article
- Receptor-targeted engineered probiotics mitigate lethal Listeria infection.Nature communications · 2020Article
- Review
- Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy.Current microbiology · 2019Review
- Lactobacillus casei expressing Internalins A and B reduces Listeria monocytogenes interaction with Caco-2 cells in vitro.Microbial biotechnology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enteric infections account for high morbidity and mortality and are considered to be the fifth leading cause of death at all ages worldwide. Seventy percent of all enteric infections are foodborne. Thus significant efforts have been directed toward the detection, control and prevention of foodborne diseases. Many antimicrobials including antibiotics have been used for their control and prevention. However, probiotics offer a potential alternative intervention strategy owing to their general health beneficial properties and inhibitory effects against foodborne pathogens. Often, antimicrobial probiotic action is non-specific and non-discriminatory or may be ineffective. In such cases, bioengineered probiotics expressing foreign gene products to achieve specific function is highly desirable. In this review we summarize the strategic development of recombinant bioengineered probiotics to control enteric infections, and to examine how scientific advancements in the human microbiome and their immunomodulatory effects help develop such novel and safe bioengineered probiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.